Blue California completes groundbreaking human clinical trial on ErgoActive® ergothioneine intervention for cognitive function, memory, and sleep
05 févr. 2024 04h00 HE
|
Blue California Ingredients
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California, an industry leader in science-driven ingredient development, announced the successful completion of a...
Signs of Healthy Aging Found in Ergothioneine Telomere Study
10 déc. 2020 04h58 HE
|
Blue California ingredients
RANCHO SANTA MARGARITA, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- An in vitro study published in the Journal of Dietary Supplements, demonstrated Blue California’s ErgoActive® ergothioneine helped...
Blue California Files Patent on the Use of Ergothioneine as a Support for Oxidative Stress Related Health Conditions, including COVID-19
14 juil. 2020 17h37 HE
|
Blue California Ingredients
Rancho Santa Margarita, Calif and Bedford, Mass., July 14, 2020 (GLOBE NEWSWIRE) -- Blue California, a science-based, innovative ingredient solution provider, has just filed for a patent on...
Entia Biosciences, Inc. (OTCQB: ERGO) Receives Notification of the Grant of European Patent it has Exclusively Licensed for Identifying the Ergothioneine Transporter and its Therapeutic Uses
02 nov. 2016 15h20 HE
|
Entia Biosciences, Inc.
PORTLAND, Ore., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) has been informed that the European Patent Office has granted European Patent Number 1 761 784 with the title...
Entia Biosciences, Inc. (OTCQB: ERGO) to Present Results of Chronic Kidney Disease Medical Food Clinical Study at American Society of Nephrology / Kidney Week 2016 Annual Meeting
06 oct. 2016 12h52 HE
|
Entia Biosciences, Inc.
PORTLAND, Ore., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) was informed by the American Society of Nephrology (“ASN”) that its submission of “late breaking clinical...
Preliminary clinical results for Entia Biosciences, Inc.’s new, proprietary ErgoD2® medical food show an average increase in kidney filtration rate of approximately 10% for over 75% of test subjects, after only three months
26 sept. 2016 08h30 HE
|
Entia Biosciences, Inc.
PORTLAND, Ore., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported better-than-expected...
UPDATE -- Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
21 déc. 2015 15h12 HE
|
Entia Biosciences, Inc.
PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected...
Entia Biosciences, Inc. Begins Clinical Study of Proprietary ErgoD2® Medical Food Product to Demonstrate Improved Health for the More Than 25 Million Chronic Kidney Disease Sufferers in the U.S.
21 déc. 2015 08h50 HE
|
Entia Biosciences, Inc.
PORTLAND, Ore., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) Founder and Chief Science and Technology Officer, Dr. Marvin Hausman, has reported greater-than-expected...